Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery

Inclusion Criteria: * Patients must have histologically or cytologically confirmed pancreatic adenocarcinoma * Patients may have locally advanced disease, not amenable to curative resection; the site of pancreatic cancer must be amenable to endoscopic ultrasound (EUS) injection; patients with newly diagnosed metastatic disease of small volume may be included in the study at the investigator's discretion; such patients would be limited to those with: * Liver involvement \< 10% of volume and no metastasis \> 2 cm, and/or * Pulmonary involvement with no respiratory compromise and no metastasis \> 2cm and/or * Peritoneal disease and no metastasis \> 2 cm and without ascites (as might be found on exploratory laparoscopy) * Eastern Cooperative Oncology Group (ECOG) performance status =\< 1 (Karnofsky \>= 80%) * Patients (in the opinion of the principal investigator) should be able to complete a full 3-month course of vaccination preferably with an anticipated survival of 6 months or longer * Leukocytes \>= 3,000/mcL * Hemoglobin \>= 8 gms/dL * Absolute neutrophil count \>= 1,500/mcL * Platelets \>= 100,000/mcL * Total bilirubin =\< 1.5 X institutional upper limit of normal * Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 X institutional upper limit of normal * Prothrombin time (PT)/partial thromboplastin time (PTT) within normal institutional limits * A…